Helicobacter pylori virulence factors (H. pylori virulence factors)

Helicobacter pylori virulence factors are a diverse array of bacterial molecules and systems that enable the pathogen to colonize the human gastric mucosa and cause disease (NIH, 2023). Key factors include the enzyme urease, which neutralizes stomach acid by producing ammonia, and the flagella, which provide the motility necessary to penetrate the mucus layer (Wikipedia, 2024). Major toxins such as Vacuolating cytotoxin A (VacA) and Cytotoxin-associated gene A (CagA) are delivered into host cells, where they disrupt signaling, induce apoptosis, and promote inflammation (NIH, 2019). Adhesins like Blood group antigen-binding adhesin (BabA) and Sialic acid-binding adhesin (SabA) facilitate persistent attachment to the gastric epithelium (MDPI, 2023). These factors are central to the pathogenesis of chronic gastritis, peptic ulcers, and gastric cancer, making them primary targets for therapeutic intervention (NIH, 2023). Current treatments utilize a combination of antibiotics and acid-suppressing drugs to eradicate the bacteria, while research into specific virulence inhibitors and vaccines continues to address rising antibiotic resistance (ResearchGate, 2023). Eradication of these factors is essential for preventing the progression of gastric malignancies (NIH, 2023).

Other names

H. pylori pathogenicity factorsH. pylori effector proteinsH. pylori colonization factorsHelicobacter pylori virulence proteins

Drugs targeting Helicobacter pylori virulence factors primarily work by inhibiting bacterial survival, growth, and colonization. Antibiotics like amoxicillin and clarithromycin inhibit cell wall and protein synthesis, respectively (NIH, 2023). Bismuth compounds disrupt bacterial membranes and interfere with adhesion (ResearchGate, 2023). Proton pump inhibitors (PPIs) and potassium-competitive acid blockers (P-CABs) like vonoprazan increase gastric pH, which inhibits the acid-dependent activity of certain virulence factors like urease and enhances antibiotic efficacy (NIH, 2023). Experimental agents like acetohydroxamic acid specifically target the urease enzyme to prevent acid neutralization (NIH, 2019).